August 01, 2007 Archives - Renal and Urology News

Print Issue: August 01, 2007

PCa Vaccine Followed by Docetaxel Beneficial

ANAHEIM, Calif.—Men with androgen independent prostate cancer (AIPC) who have received initial treatment with sipuleucel-T (Provenge) followed by docetaxel after progression of their disease may have prolonged survival, according to new findings presented here at the American Urological Association annual meeting.

PCa Treatment Type Affects ED Therapy

QUEBEC CITY—A Canadian study of men with erectile dysfunction (ED) following prostate cancer therapy showed that those who received radiation therapy alone had greater success with ED treatment than men treated with radical prostatectomy alone or in combination with radiation.

Small Renal Masses Often Not A Threat

QUEBEC CITY—Two Canadian studies characterizing the natural history of renal masses in elderly patients—many with significant comorbidities—may help to define when active surveillance is appropriate management in this population.

PCa Death Decline Tied To Screening

ANAHEIM, Calif.—Declines in prostate cancer deaths are associated with an increase in PSA screening, although the effect is greater in white than in black men, according to researchers at the University of Alabama-Birmingham.

Low Testosterone May Increase Mortality

TORONTO—Androgen deficiency in men aged 50 years and older may be associated with an increased risk of death, independent of adiposity and lifestyle choices, a study suggests. This association may be explained, in part, by the metabolic syndrome and elevated markers of inflammation.